Bárbara Cancho Castellano

Dr. Bárbara Cancho Castellano

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2024 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
ICIsis Cerezo
Isis Cerezo
BCBárbara Cancho Castellano
Bárbara Cancho Castellano
JSJorge Alberto Rodriguez Sabillon
Jorge Alberto Rodriguez Sabillon
JSJorge Alberto Rodríguez Sabillón
Jorge Alberto Rodríguez Sabillón
ALAlvaro Alvarez Lopez
Alvaro Alvarez Lopez
NRNicolás Roberto Robles
Nicolás Roberto Robles
Aims: Serum creatinine and albuminuria are the core of most CKD prediction and progression risk models. Several biomarkers have been introduced to improve these results such as beta‐2‐microglobulin (B2M) and cystatin C (CysC). Nevertheless, few clinical comparisons of these biomarkers are available. We have compared serum B2M levels with albuminuria, CysC levels, and the CKD‐EPI GFR equations.Designs and Methods: A sample of 434 patients were studied: 234 males and 200 females, the mean age was 58.3 ± 15.0 years, and 33.4% have diabetes mellitus. In all patients, plasma B2M, CysC, creatinine, and urinary albumin excretion were analyzed. EGFR was calculated using CKD‐EPI equations for creatinine, CysC, and creatinine‐CysC. The risk of death and CKD progression was evaluated using ROC curves and Cox proportional hazards survivorship models.Results: For mortality, the highest area under the curve (AUC) was for CysC (0.775, 0.676–0.875). The lowest sensitivity was shown by eGFR (creatinine) (0.298, 0.195–0.401, p < 0.001), eGFR (CysC) (0.216, 0.118–0.314, p < 0.001), and eGFR (creatinine + CysS) (0.218, 0.124–0.312, p < 0.001). For progression to advanced CKD, the highest AUC was for CysC (0.908, 0.862–0.954). The lowest sensitivity was shown by eGFR (creatinine) (0.184, 0.106–0.261, p < 0.001), eGFR (CysC) (0.095, 0.048–0.14, p < 0.001), and eGFR (creatinine+ CysC) (0.087, 0.040–0.134, p < 0.001). CysC, after age, was the second‐best marker of life risk. Contrariwise, for CKD progression, CysC, and albuminuria were the best markers.Conclusions: The best biomarker of mortality and risk of progression to CKD was CysC. Albuminuria and B2M were the next best options to be used. The lowest sensitivity was shown by estimated eGFR.

10 October 2025 in European Journal of Internal Medicine
Verified
Journal Article
Open access
LGLaura González-Rodríguez
Laura González-Rodríguez
MAManuel Martí Antonio
Manuel Martí Antonio
SMSonia Mota-Zamorano
Sonia Mota-Zamorano
CCCelia Chicharro
Celia Chicharro
BCBárbara Cancho Castellano
Bárbara Cancho Castellano
Guillermo GervasiniGuillermo Gervasini
Guillermo Gervasini
Cardiovascular (CV) complications are the leading cause of death in patients with chronic kidney disease (CKD). Endothelin-1 (ET-1), a potent vasoconstrictor involved in both renal and vascular dysfunction, may represent a promising biomarker for the disease. ET-1 plasma levels were quantified in 692 Spanish CKD patients (stages 1-5) and used to stratify individuals into three clusters (cluster 3 meaning highest concentrations). Associations with CKD progression, CVE, and all-cause mortality were assessed over a mean follow-up of 48.6 ± 27.4 months using linear mixed-effects models and Cox regression analyses adjusted for conventional risk factors. ET-1 levels increased with CKD severity (mean±SD: 1.65 ± 0.71 pg/mL for stages 1-2; 1.82 ± 0.71 pg/mL for stage 3; 2.39 ± 1.08 pg/mL for stages 4-5; p < 0.001). Higher ET-1 levels were independently associated with accelerated eGFR decline over 3 years (β = -12.64, p < 0.001 for cluster 2; and β = -11.71, p = 0.034 for cluster 3). Sixty-nine CVE (10.1 %) were recorded. Participants with higher ET-1 levels had significantly lower CV event-free survival [HR = 2.24 (1.12-4.45), p = 0.022, and HR = 2.50 (1.09-5.73), p = 0.03] for clusters 2 and 3, respectively. ET-1 also predicted all-cause mortality (p < 0.001) although the association lost significance after adjusting for age. Random forest models for CV risk and all-cause mortality including the ET-1 cluster produced C-indices of 0.835 and 0.837, respectively. Elevated ET-1 levels are independently associated with both CKD progression and CV complications. ET-1 may serve as a dual biomarker for renal deterioration and CV risk, potentially improving clinical stratification in CKD management.

21 February 2024 in Medicina Clinica
Verified
Journal Article
Open access
BCBárbara Cancho Castellano
Bárbara Cancho Castellano
ALAlvaro Alvarez Lopez
Alvaro Alvarez Lopez
JVJulian Valladares
Julian Valladares
JSJorge Alberto Rodríguez Sabillón
Jorge Alberto Rodríguez Sabillón
JGJuan Lopez Gomez
Juan Lopez Gomez
NRNicolás Roberto Robles
Nicolás Roberto Robles
Objectives: Cystatin C is increasingly used as a marker of renal function as a complement to serum creatinine and glomerular filtration rate (GFR). We have assessed its efficacy as a predictor of mortality in a group of patients with increased cystatin C but GFR > 60 mL/min. Design and methods: We included 608 patients, 65.9% male, 34.6% had diabetes mellitus. The mean age was 58.5 +/- 14.5 years and a mean GFR of 64.1 +/- 33.5 mL/min. Patients were divided into 3 groups: CONTROL (normal cystatin C and GFR > 60 mL/min, age 53.3 +/- 12.8 years, GFR 96.6 +/- 22.4 mL/min,n = 193), INCREASED CYSTATIN (cystatin C >1.03 mg/l and GFR >60 mL/min, age 58.9 +/- 13,1 years, GFR 72.2 +/- 10.4 mL/min, n = 40) and CKD (chronic kidney disease, increased cystatin C and GFR < 60 mL/min, age 61.4 +/- 14.8 years, GFR 36.0 +/- 12.7 mL/min, n = 160). The relationship with overall mortality was analyzed using the KaplanMeier method. Results: Mean cystatin C was 0.75 +/- 0.13 versus 1.79 +/- 0.54 in CKD group and 1.14 +/- 0.14 mg/l, p < 0.001). In CONTROL group survival was 93.9% at 5 y, compared to 78.8% in the ERC group and 82.3% in the INCREASED CYSTATIN group (p < 0.001) Five-year survival before renal replacement therapy was also different for the ERC group (73%, p < 0.001 Log Rank) but not between the other two groups (CONTROL 99.0%, INCREASED CYSTATIN 94.3% p = 0.08). Conclusions: Increased plasmatic levels of cystatin C in patients with GFR > 60 mL/min was a predictor of increased mortality but not of progression to end-stage renal failure. These results confirm the interest of routinely measuring cystatin C. (c) 2024 The Author(s). Published by Elsevier Espania, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

27 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LGLaura González-Rodríguez
Laura González-Rodríguez
MAManuel Martí Antonio
Manuel Martí Antonio
VAVirginia Diaz Acevedo
Virginia Diaz Acevedo
SMSonia Mota-Zamorano
Sonia Mota-Zamorano
CCCelia Chicharro
Celia Chicharro
Guillermo GervasiniGuillermo Gervasini
Guillermo Gervasini
Background: Chronic kidney disease (CKD) markedly increases the risk of cardiovascular events (CVE), yet conventional biomarkers often fail to capture this excess risk. We evaluated whether circulating levels and genetic variability within the FGF19/β-Klotho/FGFR axis contribute to CV risk stratification in CKD. Methods: In 579 CKD patients, plasma FGF19 and β-Klotho concentrations were quantified, and 64 genetic variants across FGF19, KLB, FGFR1, and FGFR4 genes were analyzed. Results: Cluster analysis identified three distinct biomarker profiles, with one cluster—characterized by low/intermediate FGF19 and markedly elevated β-Klotho—showing significantly reduced CV event-free survival. After adjustment for clinical covariates, this cluster was independently associated with higher CV risk [HR = 2.97 (1.12–7.92), p = 0.029]. Two genetic variants also showed independent associations: FGFR1 rs2288696 (protective) [HR = 0.51 (0.27–0.95), p = 0.029] and KLB rs2687971 (risk-increasing) [HR = 2.03 (0.97–4.27), p = 0.046]. A combined CV risk model incorporating biomarker clusters, relevant SNPs, and traditional risk factors achieved good discriminative ability (C-index = 0.80), with the FGF19/β-Klotho cluster showing predictive importance comparable to diabetes and previous CV history. Conclusions: These results indicate that integrating FGF19-Klotho biomarkers with genetic information may improve CV risk prediction in CKD.

19 December 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
LGLaura González-Rodríguez
Laura González-Rodríguez
MAManuel Martí Antonio
Manuel Martí Antonio
VAVirginia Diaz Acevedo
Virginia Diaz Acevedo
SMSonia Mota-Zamorano
Sonia Mota-Zamorano
CCCelia Chicharro
Celia Chicharro
Guillermo GervasiniGuillermo Gervasini
Guillermo Gervasini
Chronic kidney disease (CKD) markedly increases the risk of cardiovascular events (CVE), yet conventional biomarkers often fail to capture this excess risk. We evaluated whether circulating levels and genetic variability within the FGF19/β-Klotho/FGFR axis contribute to CV risk stratification in CKD. In 579 CKD patients, plasma FGF19 and β-Klotho con-centrations were quantified, and 64 genetic variants across FGF19, KLB, FGFR1 and FGFR4 genes were analyzed. Cluster analysis identified three distinct biomarker profiles, with one cluster—characterized by low/intermediate FGF19 and markedly elevated β-Klotho—showing significantly reduced CV event-free survival. After adjustment for clinical covariates, this cluster was independently associated with higher CV risk [HR=2.97 (1.12–7.92), p=0.029]. Two genetic variants also showed independent associa-tions: FGFR1 rs2288696 (protective) [HR=0.51 (0.27–0.95), p=0.029] and KLB rs2687971 (risk-increasing) [HR=2.03 (0.97–4.27), p=0.046]. A combined CV risk model incorporating biomarker clusters, relevant SNPs and traditional risk factors achieved good discrimina-tive ability (C-index = 0.80), with the FGF19/β-Klotho cluster showing predictive im-portance comparable to diabetes and previous CV history. These findings suggest that in-tegrating FGF19-Klotho biomarkers with genetic information may enhance CV risk pre-diction in CKD.